

Dongfen Yuan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4830161/publications.pdf>

Version: 2024-02-01

13
papers

1,260
citations

840119

11
h-index

1058022

14
g-index

14
all docs

14
docs citations

14
times ranked

2256
citing authors

#	ARTICLE	IF	CITATIONS
1	Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 195-204.	1.7	469
2	Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. <i>Biomaterials</i> , 2017, 142, 1-12.	5.7	411
3	Physiologically Based Pharmacokinetic Modeling of Nanoparticles. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 58-72.	1.6	105
4	Effect of Octreotideâ€™ Polyethylene Glycol(100) Monostearate Modification on the Pharmacokinetics and Cellular Uptake of Nanostructured Lipid Carrier Loaded with Hydroxycamptothecine. <i>Molecular Pharmaceutics</i> , 2011, 8, 1641-1651.	2.3	58
5	Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs. <i>Pharmaceutics</i> , 2019, 11, 110.	2.0	49
6	A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery. <i>Journal of Controlled Release</i> , 2010, 146, 299-308.	4.8	43
7	Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity. <i>Journal of Controlled Release</i> , 2014, 191, 34-46.	4.8	40
8	Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity. <i>Journal of Controlled Release</i> , 2017, 263, 172-184.	4.8	28
9	Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor <i>in vitro</i> and <i>in vivo</i>. <i>Drug Delivery</i> , 2016, 23, 3562-3572.	2.5	19
10	Luteinizing Hormone Releasing Hormone-Targeted Cisplatin-Loaded Magnetite Nanoclusters for Simultaneous MR Imaging and Chemotherapy of Ovarian Cancer. <i>Chemistry of Materials</i> , 2016, 28, 3024-3040.	3.2	15
11	A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies. <i>AAPS Journal</i> , 2018, 20, 48.	2.2	13
12	Downregulation of Interferon- γ Receptor Expression Endows Resistance to Anti-Programmed Death Protein 1 Therapy in Colorectal Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 21-28.	1.3	5
13	A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 138, 105032.	1.9	4